BR112022007328A2 - Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática - Google Patents

Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática

Info

Publication number
BR112022007328A2
BR112022007328A2 BR112022007328A BR112022007328A BR112022007328A2 BR 112022007328 A2 BR112022007328 A2 BR 112022007328A2 BR 112022007328 A BR112022007328 A BR 112022007328A BR 112022007328 A BR112022007328 A BR 112022007328A BR 112022007328 A2 BR112022007328 A2 BR 112022007328A2
Authority
BR
Brazil
Prior art keywords
derivative
neuropathic pain
compound
phenylquinolinone
treatment
Prior art date
Application number
BR112022007328A
Other languages
English (en)
Inventor
Lou Jinfang
Zhang Fengmin
Sheng Rong
Jin Zewu
Original Assignee
Hangzhou Bio Sincerity Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Bio Sincerity Pharma Tech Co Ltd filed Critical Hangzhou Bio Sincerity Pharma Tech Co Ltd
Publication of BR112022007328A2 publication Critical patent/BR112022007328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE DERIVADO DE FENILQUINOLINONA OU DERIVADO DE FLAVONÓIDE PARA TRATAMENTO DE DOR NEUROPÁTICA. A presente invenção fornece o uso de derivado de fenilquinolinona ou derivado de flavonóide para dor neuropática. Além disso, o derivado de fenilquinolinona ou derivado de flavonóide compreende seus sais farmaceuticamente aceitáveis. O composto da presente invenção é um antagonista do receptor H3 da histamina, possui um mecanismo de ação diferente dos fármacos existentes, podendo ser utilizado na preparação de fármacos para o tratamento de doenças dolorosas neuropáticas. O efeito do composto da presente invenção para o tratamento da dor neuropática é superior ao da amitriptilina, gabapentina, pregabalina e carbamazepina. Portanto, o composto da presente invenção tem um melhor efeito de tratamento e tem as características de uma dosagem pequena, boa eficácia do medicamento, alta biodisponibilidade e alta segurança. Comparado com os opióides, o composto da presente invenção não possui propriedades de dependência e é uma droga muito eficaz para o tratamento de doenças de dor neuropática. Portanto, o composto tem uma grande perspectiva de aplicação clínica.
BR112022007328A 2019-10-15 2019-10-15 Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática BR112022007328A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/111269 WO2021072642A1 (zh) 2019-10-15 2019-10-15 苯基喹啉酮类和黄酮类衍生物治疗神经病理性疼痛的用途

Publications (1)

Publication Number Publication Date
BR112022007328A2 true BR112022007328A2 (pt) 2022-07-05

Family

ID=75537408

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007328A BR112022007328A2 (pt) 2019-10-15 2019-10-15 Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática

Country Status (11)

Country Link
US (1) US20230295134A1 (pt)
EP (1) EP4046638A4 (pt)
JP (1) JP2023506119A (pt)
KR (1) KR20220084133A (pt)
CN (1) CN114599362A (pt)
AU (1) AU2019470618A1 (pt)
BR (1) BR112022007328A2 (pt)
CA (1) CA3154920A1 (pt)
MX (1) MX2022004610A (pt)
WO (1) WO2021072642A1 (pt)
ZA (1) ZA202205337B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230382910A1 (en) * 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087024B (zh) * 2013-01-15 2014-11-19 四川大学 一类黄酮烷基胺类化合物、其制备方法和用途
CN109111400B (zh) * 2017-06-23 2020-10-16 杭州百诚医药科技股份有限公司 苯基喹啉酮类和黄酮类衍生物的制备和应用
CN109651321B (zh) * 2019-01-31 2020-06-26 南阳师范学院 一种芹菜素-o-烷基胺类化合物、制备方法和应用

Also Published As

Publication number Publication date
MX2022004610A (es) 2022-07-19
AU2019470618A1 (en) 2022-05-12
KR20220084133A (ko) 2022-06-21
EP4046638A1 (en) 2022-08-24
ZA202205337B (en) 2022-10-26
US20230295134A1 (en) 2023-09-21
CA3154920A1 (en) 2021-04-22
CN114599362A (zh) 2022-06-07
WO2021072642A1 (zh) 2021-04-22
JP2023506119A (ja) 2023-02-15
EP4046638A4 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
US10220038B2 (en) Pharmaceutical combinations
CA2851996C (en) Pharmaceutical compositions for substituted quinazolinones
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
De Doncker et al. Itraconazole: What clinicians should know?
CA3018635C (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
JP6804497B2 (ja) Ｌ−４−クロロキヌレニンの剤形及び治療的使用
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112012017884A2 (pt) composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres
BR112014007223A2 (pt) derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos
JP2015214579A (ja) 癌細胞アポトーシス
BR112021026554A2 (pt) Antagonista de neurocinina-1
BR112022007328A2 (pt) Uso de derivado de fenilquinolinona ou derivado de flavonóide para tratamento de dor neuropática
BR112014032244A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112019005214A2 (pt) composição farmacêutica compreendendo antagonista do receptor de mineralocorticoide e uso da mesma
BR112015030953A8 (pt) compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos
BR112015031835A8 (pt) agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
BR112015009504A2 (pt) inibidores de rock